心絞痛是心臟冠狀動(dòng)脈供血不足引起的心肌急劇性、暫時(shí)性的缺血與缺氧綜合征，主要原因是心臟氧供需之間的失衡。盡管臨床治療有效，但在心絞痛控制方面仍存在顯著性差異，這不僅對(duì)病人的生活質(zhì)量產(chǎn)生影響，同時(shí)造成醫(yī)療費(fèi)用的增加。為了對(duì)心絞痛治療臨床試驗(yàn)的開(kāi)展及研究提供參考，筆者查閱國(guó)內(nèi)外最新研究報(bào)道，分析總結(jié)了目前心絞痛的治療藥物，包括已上市藥物的最新臨床試驗(yàn)和在研藥物，為治療心絞痛提供參考。

Angina pectoris is the acute temporary ischemia and hypoxia syndrome of myocardium caused by insufficient coronary blood supply, mainly due to the imbalance between supply and demand of cardiac oxygen. Although effective, there are significant differences in the control of angina pectoris, which can affect life quality and increase medical expenses. In order to provide reference for the development and research of clinical trials, the authors reviewed the latest domestic and foreign research reports, summarize the current treatment drugs for angina pectoris, including the latest clinical trials of approved drugs and investigational. In this paper, the representative drugs are reviewed.